Biogen Q3’25 Mixed Results, Lowers Full-Year EPS Outlook

$BIIB (+0,16 %)

• Product Revenue: $1.85B (Est. $1.78B) 🟢

• FY25 Adj. EPS: $14.50–$15.00 (Prev. $15.50–$16.00) 🔻

• Guidance includes ~$1.25 EPS impact from development transactions